Immunorizon Overview
Immunorizon is developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy. The company extends its pipeline and uses tri-specific constructs with additional tumor-associated antigens and diverse engagers with both T-cells and NK-cells.
Cumulative Funding Raised Over Time ($)
Latest News
No news articles.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Acquired |
| Rounds | 3 |
| Investors | 2 |
Team Members
2
Employees: 1-10
Web & Social Links
Locations
Yavne, Israel
Photos & Videos
No files yet
Immunorizon Business
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
—Core Technology
BiologicalsCellsTags (5)
cancer-therapyimmunologyoncologyantibodiesbiotechnologyImmunorizon Financials
Cumulative Funding Raised Over Time ($)
Private Equity Funding
Public Offering / Exit
Immunorizon Lifecycle
Cumulative Funding Raised Over Time
All Events
Immunorizon News
0 articlesNo news articles.
Employee Info
| Employees (range) | 1-10 |
| Exact count | 2 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 5 classification IDs that could be used for matching.
Immunorizon Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 83/100 |
| Missing | homepage, video or image, news, markets, external profiles, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 515756047 |
| Creator | Maor Perlov |
| Creator email | maorperlov@gmail.com |
| Last updater | Maor Perlov |
| Updater email | maorperlov@gmail.com |
| Last update | 2022-02-28T00:00:00.000Z |
| Created | 2022-02-28T00:00:00.000Z |
| Status detail | Acquired by Purple Biotech on Feb, 2023 |